A Model for the Stoichiometric Regulation of Blood Coagulation*

We have developed a model of the extrinsic blood coagulation system that includes the stoichiometric anticoagulants. The model accounts for the formation, expression, and propagation of the vitamin K-dependent procoagulant complexes and extends our previous model by including: (a) the tissue factor pathway inhibitor (TFPI)-mediated inactivation of tissue factor (TF)·VIIa and its product complexes; (b) the antithrombin-III (AT-III)-mediated inactivation of IIa, mIIa, factor VIIa, factor IXa, and factor Xa; (c) the initial activation of factor V and factor VIII by thrombin generated by factor Xa-membrane; (d) factor VIIIa dissociation/activity loss; (e) the binding competition and kinetic activation steps that exist between TF and factors VII and VIIa; and (f) the activation of factor VII by IIa, factor Xa, and factor IXa. These additions to our earlier model generate a model consisting of 34 differential equations with 42 rate constants that together describe the 27 independent equilibrium expressions, which describe the fates of 34 species. Simulations are initiated by “exposing” picomolar concentrations of TF to an electronic milieu consisting of factors II, IX, X, VII, VIIa, V, and VIIII, and the anticoagulants TFPI and AT-III at concentrations found in normal plasma or associated with coagulation pathology. The reaction followed in terms of thrombin generation, proceeds through phases that can be operationally defined as initiation, propagation, and termination. The generation of thrombin displays a nonlinear dependence upon TF, AT-III, and TFPI and the combination of these latter inhibitors displays kinetic thresholds. At subthreshold TF, thrombin production/expression is suppressed by the combination of TFPI and AT-III; for concentrations above the TF threshold, the bolus of thrombin produced is quantitatively equivalent. A comparison of the model with empirical laboratory data illustrates that most experimentally observable parameters are captured, and the pathology that results in enhanced or deficient thrombin generation is accurately described.

[1]  K. Mann,et al.  Phospholipid-binding properties of bovine factor V and factor Va. , 1979, Biochemistry.

[2]  K. Mann,et al.  Isolation and characterization of single chain bovine factor V. , 1979, The Journal of biological chemistry.

[3]  K. Mann,et al.  Interaction of coagulation factor V and factor Va with platelets. , 1979, The Journal of biological chemistry.

[4]  G M Oosta,et al.  The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. , 1980, The Journal of biological chemistry.

[5]  K. Mann,et al.  Isolation of functional human coagulation factor V by using a hybridoma antibody. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[6]  K. Mann,et al.  [21] Factor V , 1981 .

[7]  K. Mann,et al.  The factor Xa-catalyzed activation of factor V. , 1983, The Journal of biological chemistry.

[8]  Monoclonal antibodies selective for activated Factor V. Immunochemical probes for structural transitions occurring during the thrombin-catalyzed activation of the procofactor. , 1983, The Journal of biological chemistry.

[9]  R. Colman,et al.  Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variants. , 1983, The Journal of clinical investigation.

[10]  K. Mann,et al.  "Clotspeed," a mathematical simulation of the functional properties of prothrombinase. , 1984, The Journal of biological chemistry.

[11]  K. Mann,et al.  Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. , 1987, The Journal of biological chemistry.

[12]  P. Schoen,et al.  The in situ inhibition of prothrombinase-formed human alpha-thrombin and meizothrombin(des F1) by antithrombin III and heparin. , 1987, The Journal of biological chemistry.

[13]  C. Beresford Antithrombin III deficiency. , 1988, Blood reviews.

[14]  C. Esmon,et al.  The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.

[15]  K. Mann,et al.  Multiple active forms of thrombin. IV. Relative activities of meizothrombins. , 1990, The Journal of biological chemistry.

[16]  V. V. van Hinsbergh,et al.  Extrinsic activation of human coagulation factors IX and X on the endothelial surface. , 1991, Thrombosis and haemostasis.

[17]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[18]  P. Lollar,et al.  Coagulant properties of hybrid human/porcine factor VIII molecules. , 1992, The Journal of biological chemistry.

[19]  S Krishnaswamy,et al.  The interaction of human factor VIIa with tissue factor. , 1992, The Journal of biological chemistry.

[20]  G. Broze,et al.  Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.

[21]  K. Mann,et al.  Extrinsic pathway proteolytic activity. , 1993, Methods in enzymology.

[22]  K. Mann,et al.  Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. , 1993, The Journal of biological chemistry.

[23]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. I. An empirical study. , 1994, The Journal of biological chemistry.

[24]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[25]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. II. A mathematical simulation. , 1994, The Journal of biological chemistry.

[26]  J. McVey,et al.  Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). , 1994, Biochemistry.

[27]  H C Hemker,et al.  Analysis of thrombin generation in plasma. , 1994, Computers in biology and medicine.

[28]  P. Reitsma,et al.  Homozygosity for a Novel Missense Mutation in the Prothrombin Gene Causing a Severe Bleeding Disorder , 1994, Thrombosis and Haemostasis.

[29]  K. Mann,et al.  Cooperative interaction of divalent metal ions, substrate, and tissue factor with factor VIIa. , 1994, Biochemistry.

[30]  Y. Nemerson,et al.  A microscopic model of enzyme kinetics. , 1995, Biophysical journal.

[31]  J Jesty,et al.  Mathematical analysis of activation thresholds in enzyme-catalyzed positive feedbacks: application to the feedbacks of blood coagulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  K. Mann,et al.  Blood clotting in minimally altered whole blood. , 1996, Blood.

[33]  K. Mann,et al.  Kinetics of human factor VII activation. , 1996, Biochemistry.

[34]  R. Kaufman,et al.  Model for the Factor VIIIa-dependent Decay of the Intrinsic Factor Xase , 1996, The Journal of Biological Chemistry.

[35]  P. Bolton-Maggs 10 Factor XI deficiency , 1996 .

[36]  R J Baugh,et al.  Role of the Activation Peptide Domain in Human Factor X Activation by the Extrinsic Xase Complex* , 1996, The Journal of Biological Chemistry.

[37]  M N Liebman,et al.  Qualitative modeling of normal blood coagulation and its pathological states using stochastic activity networks. , 1997, International journal of biological macromolecules.

[38]  Kenneth G. Mann,et al.  Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation , 1997, The Journal of Biological Chemistry.

[39]  P. Reitsma Protein C Deficiency: from Gene Defects to Disease , 1997, Thrombosis and Haemostasis.

[40]  K. Mann,et al.  Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine Proteases* , 1997, The Journal of Biological Chemistry.

[41]  Kenneth G. Mann,et al.  Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* , 1997, The Journal of Biological Chemistry.

[42]  P. Mannucci,et al.  Screening Tests for Thrombophilic Patients: Which Tests, for Which Patient, by Whom, When, and Why? , 1998, Seminars in thrombosis and hemostasis.

[43]  G. Broze,et al.  Regulation of Extrinsic Pathway Factor Xa Formation by Tissue Factor Pathway Inhibitor* , 1998, The Journal of Biological Chemistry.

[44]  K. Mann,et al.  Blood coagulation in hemophilia A and hemophilia C. , 1998, Blood.

[45]  Kenneth G. Mann,et al.  An Integrated Study of Fibrinogen during Blood Coagulation* , 1999, The Journal of Biological Chemistry.

[46]  B. Dahlbäck,et al.  Thrombophilia as a multigenic disease. , 1999, Haematologica.

[47]  T S Edgington,et al.  Macromolecular Substrate Affinity for the Tissue Factor-Factor VIIa Complex Is Independent of Scissile Bond Docking* , 1999, The Journal of Biological Chemistry.

[48]  K. Mann,et al.  A model describing the inactivation of factor Va by APC: bond cleavage, fragment dissociation, and product inhibition. , 1999, Biochemistry.

[49]  K. Mann,et al.  "Normal" thrombin generation. , 1999, Blood.

[50]  C. Esmon Regulation of blood coagulation. , 2000, Biochimica et biophysica acta.

[51]  K. Mann,et al.  Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. , 2000, Blood.

[52]  W Ruf,et al.  Exosite Interactions Determine the Affinity of Factor X for the Extrinsic Xase Complex* , 2000, The Journal of Biological Chemistry.

[53]  S. Olson,et al.  Heparin Enhances the Specificity of Antithrombin for Thrombin and Factor Xa Independent of the Reactive Center Loop Sequence , 2001, The Journal of Biological Chemistry.

[54]  W. Ruf,et al.  Role of Zymogen and Activated Factor X as Scaffolds for the Inhibition of the Blood Coagulation Factor VIIa-Tissue Factor Complex by Recombinant Nematode Anticoagulant Protein c2* , 2001, The Journal of Biological Chemistry.

[55]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.